Collectively, these studies suggest that mTOR is a critical regulatory signal in the de novo purine biosynthetic pathway by influencing purinosome and mitochondria interaction and amino acid substrates, which further reprogram metabolic responses in cancer cells (Figure 3). This evidence concerns the gene MTOR and cancer.